Evidence map›Paper›PMID 39722127›Full record

ReviewTissue barriers2025

Claudins in vulvar cancer - from epithelial barrier to potential tumor-agnostic cancer therapy.

Gilbert Georg Klamminger, Annick Bitterlich, Meletios P Nigdelis, Martin Ertz, Kim Yoo-Jin, Annette Hasenburg, Mathias Wagner

Abstract readReview
In one paragraph

Review in Tissue barriers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gilbert Georg KlammingerDepartment of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.ORCID 0000-0001-5358-2751
Annick BitterlichDepartment of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.
Meletios P NigdelisDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), Homburg, Germany.
Martin ErtzDepartment of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.
Kim Yoo-JinDepartment of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.
Annette HasenburgDepartment of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Mathias WagnerDepartment of General and Special Pathology, Saarland University (USAAR) and Saarland University Medical Center (UKS), Homburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunohistochemical expression of various members of the claudin family has already been studied in pathological affections of the vulva whether to differentiate precancerous lesions from vulvar squamous cell carcinoma or in inflammatory conditions such as lichen sclerosus. From an oncological perspective, however, immunohistochemical analysis of claudin 18.2 protein expression has become increasingly clinically relevant nowadays since the impressive therapeutic benefits of the claudin 18.2 antibody

Indexed as

ClaudinsVulvar NeoplasmsCarcinoma, Squamous CellFemaleHumansClaudinsClaudinclaudin 18.2immunohistochemistrysquamous cell carcinomatight junctionsvulvar cancer

Identifiers

PMID39722127
PMCPMC12667638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.